Comparison of Efficacy between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome

Abstract

Objective: To compare the effectiveness of myo-inositol versus metformin in treating women with polycystic
ovary syndrome.
Study Design: Cross-sectional study.
Place and Duration of Study: The study was carried out at the Department of Gynae Unit II, Dr. Ruth. K.M. Pfau
th th Civil Hospital Karachi, Pakistan from 7 February 2019 to 6 August 2019.
Methods: All eligible patients who visited the hospital were enrolled. The group-Aincluded females who
received myo-inositol (n=35), whereas the group-B included females who received metformin (n=35). Females
in the myo-inositol group were administered 1 gram of myo-inositol twice daily, while those in the metformin
group were administered 500 mg of metformin twice daily. Regular follow-up visits were scheduled every two
months, and the efficacy of the treatment was assessed after six months. Efficacy was evaluated in terms of the
normalization of menstrual cycles and the achievement of ovulation.
Results: The mean age in the myo-inositol and metformin groups was 23.92±3.70 and 23.68±4.23, respectively.
The mean weight in the myoinositol and metformin groups was 59.23±2.07 and 61.79±5.92, respectively.
Notably, the efficacy rates for the myo-inositol and metformin groups were 68.57% and 20%, respectively with
p-value=0.001.
Conclusion: Myo-inositol was found to demonstrate significant superiority over metformin in the treatment of
polycystic ovary syndrome.

How to cite this: Latif N, Rajar S, Yousuf M, Imtiaz S, Abbas S, Jamali Z. Comparison of Efficacy Between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome. Life and Science. 2024; 5(1): 48-53. doi: http://doi.org/10.37185/LnS.1.1.486